Initiation of HIV pre-exposure prophylaxis among youth in the United States, 2015–2018

References

• Arnett, J. J. (2005). The developmental context of substance use in emerging adulthood. Journal of Drug Issues, 35(2), 235–254. https://doi.org/10.1177/002204260503500202
   Web of Science ®Google Scholar
• Arnold, T., Brinkley-Rubinstein, L., Chan, P. A., Perez-Brumer, A., Bologna, E. S., Beauchamps, L., Johnson K., Mena, L., Nunn, A. (2017). Social, structural, behavioral and clinical factors influencing retention in pre-exposure prophylaxis (PrEP) care in Mississippi. PLoS One, 12(2), e0172354. https://doi.org/10.1371/journal.pone.0172354
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. (November 2018). HIV Surveillance Report, 2017. http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html
   Google Scholar
• Centers for Disease Control and Prevention. (2021a). Estimated HIV incidence and prevalence in the United States, 2015–2019. HIV Surveillance Supplemental Report 2021. http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html
   Google Scholar
• Centers for Disease Control and Prevention. (2021b). Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2019. http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html
   Google Scholar
• Centers for Disease Control and Prevention. (2021c). Pre-exposure prophylaxis for the prevention of HIV Infection in the United States–2021 Update: A clinical practice guideline. https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf
   Google Scholar
• Earlywine, J. J., Bazzi, A. R., Biello, K. B., & Klevens, R. M. (2021). High prevalence of indications for pre-exposure prophylaxis among people who inject drugs in Boston, Massachusetts. American Journal of Preventive Medicine, 60(3), 369–378. https://doi.org/10.1016/j.amepre.2020.09.011
   PubMed Web of Science ®Google Scholar
• Harris, N. S., Johnson, A. S., Huang, Y. A., Kern, D., Fulton, P., Smith, D. K., Valleroy, L. A, Hall, H. I. (2019). Vital signs: Status of human immunodeficiency virus testing, viral suppression, and HIV preexposure prophylaxis – United States, 2013–2018. MMWR. Morbidity and Mortality Weekly Report, 68(48), 1117–1123. https://doi.org/10.15585/mmwr.mm6848e1
   PubMed Web of Science ®Google Scholar
• HIV Pre-Exposure Prophylaxis Medication for Adolescents and Young Adults: A Position Paper of the Society for Adolescent Health and Medicine. (2018). Journal of Adolescent Health, 63(4), 513–516. https://doi.org/10.1016/j.jadohealth.2018.07.021
   PubMed Web of Science ®Google Scholar
• Huang, Y. A., Tao, G., Smith, D. K., & Hoover, K. W. (2021). Persistence with human immunodeficiency virus pre-exposure prophylaxis in the United States, 2012–2017. Clinical Infectious Diseases, 72(3), 379–385. https://doi.org/10.1093/cid/ciaa037
   PubMed Web of Science ®Google Scholar
• Jo, Y., Bartholomew, T. S., Doblecki-Lewis, S., Rodriguez, A., Forrest, D. W., Tomita-Barber, J., Oves J., Tookes, H. E. (2020). Interest in linkage to PrEP among people who inject drugs accessing syringe services; Miami, Florida. PLoS One, 15(4), e0231424. https://doi.org/10.1371/journal.pone.0231424
   PubMed Web of Science ®Google Scholar
• Kann, L., McManus, T., Harris, W. A., Shanklin, S. L., Flint, K. H., Queen, B., Lowry, R., Chyen, D., Whittle, L., Thornton, J., Lim, C., Bradford, D., Yamakawa, Y., Leon, M., Brener, N., Ethier, K. A. (2018). Youth risk behavior surveillance – United States, 2017. MMWR Surveillance Summaries, 67(8), 1–114. doi:10.15585/mmwr.ss6708a1
   PubMed Web of Science ®Google Scholar
• Krishnaratne, S., Hensen, B., Cordes, J., Enstone, J., & Hargreaves, J. R. (2016). Interventions to strengthen the HIV prevention cascade: A systematic review of reviews. Lancet HIV, 3(7), e307–e317. https://doi.org/10.1016/s2352-3018(16)30038-8
   PubMed Web of Science ®Google Scholar
• Magnuson, D., Hawkins, T., & Mera, R. (2018). Adolescent use of Truvada (FTD/TDF) for HIV pre-exposure prophylaxis (PrEP) in the United States (2021 to 2017). 22nd International AIDS Conference, 23–27 July 2018, Amsterdam, The Netherlands.
   Google Scholar
• Pilkington, V., Hill, A., Hughes, S., Nwokolo, N., & Pozniak, A. (2018). How safe is TDF/FTC as PrEP? A systematic review and meta-analysis of the risk of adverse events in 13 randomised trials of PrEP. Journal of Virus Eradication, 4(4), 215–224. https://doi.org/10.1016/S2055-6640(20)30312-5
   PubMed Web of Science ®Google Scholar
• Pinto, R. M., Berringer, K. R., Melendez, R., & Mmeje, O. (2018). Improving PrEP implementation through multilevel interventions: A synthesis of the literature. AIDS and Behavior, 22(11), 3681–3691. https://doi.org/10.1007/s10461-018-2184-4
   PubMed Web of Science ®Google Scholar
• Saberi, P., Ming, K., & Dawson-Rose, C. (2018). What does it mean to be youth-friendly? Results from qualitative interviews with health care providers and clinic staff serving youth and young adults living with HIV. Adolescent Health, Medicine and Therapeutics, 9, 65–75. https://doi.org/10.2147/ahmt.S158759
   PubMed Web of Science ®Google Scholar
• Siegler, A. J., Mouhanna, F., Giler, R. M., Weiss, K., Pembleton, E., Guest, J., Jones, J., Castel, A., Yeung, H., Kramer, M., McCallister, S., Sullivan, P. S. (2018). The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis-to-need ratio in the fourth quarter of 2017, United States. Annals of Epidemiology, 28(12), 841–849. https://doi.org/10.1016/j.annepidem.2018.06.005
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration. (2018). Key substance use and mental health indicators in the United States: Results from the 2017 National Survey on Drug Use and Health. HHS Publication No. SMA 18-5068, NSDUH Series H-53. https://www.samhsa.gov/data/
   Google Scholar
• Tanner, A. E., Philbin, M. M., Duval, A., Ellen, J., Kapogiannis, B., & Fortenberry, J. D. (2014). ‘Youth friendly’ clinics: Considerations for linking and engaging HIV-infected adolescents into care. AIDS Care, 26(2), 199–205. https://doi.org/10.1080/09540121.2013.808800
   PubMed Web of Science ®Google Scholar
• Van Handel, M., Kann, L., Olsen, E. O., & Dietz, P. (2016). HIV testing among US high school students and young adults. Pediatrics, 137(2), e20152700. https://doi.org/10.1542/peds.2015-2700
   PubMed Web of Science ®Google Scholar
• Wiener, L. S., Kohrt, B. A., Battles, H. B., & Pao, M. (2011). The HIV experience: Youth identified barriers for transitioning from pediatric to adult care. Journal of Pediatric Psychology, 36(2), 141–154. https://doi.org/10.1093/jpepsy/jsp129
   PubMed Web of Science ®Google Scholar
• Yusuf, H., Fields, E., Arrington-Sanders, R., Griffith, D., & Agwu, A. L. (2020). HIV preexposure prophylaxis among adolescents in the US: A review. JAMA Pediatrics, 174(11), 1102–1108. https://doi.org/10.1001/jamapediatrics.2020.0824
   PubMed Web of Science ®Google Scholar